Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.60 |
| ▸ | BDKRB1 | P46663 | 7/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17645990 | 0.89 | BTK (0.60) | BTKBDKRB1CHUKINSRMAPK8 | |
| SCHEMBL17660316 | 0.87 | BTK (0.80) | BTK | |
| SCHEMBL17646051 | 0.86 | BTK (0.45) | BTKBDKRB1DHODH | |
| SCHEMBL17645759 | 0.85 | BTK (0.50) | BTKCHUKINSRMAPK8CAMKK2 | |
| SCHEMBL17645928 | 0.85 | BTK (0.63) | BTK | |
| SCHEMBL17645988 | 0.84 | BTK (0.56) | BTKDHODH | |
| SCHEMBL17645686 | 0.83 | BTK (0.42) | BTKDHODH | |
| SCHEMBL17645685 | 0.83 | BTK (0.42) | BTKDHODH | |
| SCHEMBL21207729 | 0.79 | BTK (0.57) | BTK | |
| SCHEMBL17664692 | 0.79 | BTK (0.46) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | BTK 1/4885BDKRB1 928/4885CHUK 121/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | BTK 1/4885BDKRB1 955/4885CHUK 112/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | BTK 1/4885BDKRB1 928/4885CHUK 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.